ReviewJournal of the Endocrine Society2022
Advances in the Development of Prodrugs as Selective Modulators of Estrogen Receptors.
Review in Journal of the Endocrine Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 5 citations in OpenAlex.
- Modular molecular design of polymerized pro-estrogen materials enables controlled astrocyte response.Journal of materials chemistry. B · 2025Article
- Theranostic Fluorescent Probes.Chemical reviews · 2024Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to the complexity of estrogen signaling mediated by estrogen receptors (ERs) in a variety of biological environments, there is great interest in the identification and optimization of selective estrogen receptor ligands. Prodrugs that can be activated in specific environments allow for tissue selectivity. Therefore, there have been recent advances in the development of prodrugs for ERs that can be released through enzymatic reactions, chemical reactions (eg, oxidation by reactive oxygen species or reduction by ascorbic acid), or light-mediated processes. In addition, researchers have linked ER ligands to additional drugs for selective cellular targeting. In this review, we highlight the compounds that have been generated and their potential uses in disease states such as breast cancer, inflammation, and menopause.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.